Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis

PRINCETON, N.J., Dec. 19, 2022. Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials